Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biovail's Orally Disintegrating Tramadol Clears FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

The company is not deciding on a brand name for tramadol ODT until it establishes a strategic marketing partner. Biovail says it is in late-stage discussions with partners for tramadol ODT and extended-release tramadol, which is "approvable" at FDA.

You may also be interested in...



Biovail To Market Tramadol Under Ortho’s Ultram Brand

The partnership for tramadol extended-release and once-daily formulations will grant Biovail use of the Ultram trade name.

Biovail To Market Tramadol Under Ortho’s Ultram Brand

The partnership for tramadol extended-release and once-daily formulations will grant Biovail use of the Ultram trade name.

Biovail’s Tramadol ER Approved Without Additional Clinical Studies

The company expects the analgesic to launch early in 2006, but continues negotiations over a marketing partnership.

Related Content

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel